AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
15 Mai 2023 - 2:45PM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), an immuno-pharma
company focused on the research and development of therapeutics to
treat multiple types of cancers, immune disorders and viral
diseases — including COVID-19, the disease caused by the SARS-CoV-2
virus — reported its financial results for the first quarter 2023
and provided a business update. As previously announced, the
Company will host a conference call and audio webcast on Tuesday,
May 16, 2023, at 8:30 AM ET (details below).
“The significant progress we have made advancing
Ampligen through numerous human clinical studies in multiple
indications has provided us with a growing body of positive data.
These data have supported and guided the prioritization of our
oncology pipeline, with pancreatic cancer as our lead development
program,” commented Thomas K. Equels, Chief Executive Officer of
AIM. “With a strong cash position and a fundamental plan to execute
across our pipeline, we are positioning the Company to achieve a
number of value-driving milestones in the near term.”
Recent Highlights
- Appointed preeminent biotechnology
pioneer W. Neal Burnette, Ph.D., as Chairman of its Scientific
Advisory Board (SAB)
- Nancy K. Bryan, pharmaceutical
industry veteran, appointed to Board of Directors
- Received central Institutional Review Board (“IRB”) approval
for the protocol of Phase 2 study evaluating Ampligen® as a
therapeutic for patients with post-COVID conditions
(“AMP-518”)
Expected Upcoming Pipeline
MilestonesQ2 2023
- Locally Advanced Pancreatic Cancer:
Enroll first patient in Phase 2 study
- Post-COVID Conditions: Enroll and
dose first patient in Phase 2 study
Q3 2023
- Advanced Recurrent Ovarian Cancer:
Announce protocol-planned interim results
Q4 2023
- Metastatic Pancreatic Cancer: Begin
clinical trial
- Post-COVID Conditions: Enroll last
patient in Phase 2 study
Summary of Financial Highlights for
First Quarter 2023
- As of March 31, 2023, AIM reported cash, cash equivalents and
marketable securities of $30.8 million. Based on management’s
current expectation, the Company’s cash runway is expected to fund
operations through multiple key milestones through the end of
2024.
- Research and development expenses for the three months ended
March 31, 2023 were $2.1 million, compared to $1.0 million for the
same period in 2022.
- General and administrative expenses were $2.3 million for the
three months ended March 31, 2023, compared to the $2.1 million for
the same period 2022.
- The net loss from operations for the three months March 31,
2023 was $3.7 million, or $0.08 per share, compared to $3.8
million, or $0.08 per share, for the three months ended March 31,
2022.
Please refer to the full 10-Q for complete
details.
Conference Call and Webcast Details
As previously announced, the Company will host a
quarterly conference call and live audio webcast to discuss the
operational and financial results on May 16, 2023, at 8:30 AM
ET.
The call will be hosted by members of AIM, CEO
Thomas K. Equels and Scientific Officer Christopher McAleer, PhD.
Interested participants and investors may access the conference
call by dialing (877) 407-9219 (domestic) or (201) 689-8852
(international) and referencing the AIM ImmunoTech Conference Call.
The live webcast will be accessible on the Events page of the
Investors section of the Company’s website, aimimmuno.com, and will
be archived for 90 days following the live event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on Twitter, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,”
“expect,” “plan,” “anticipate” and similar expressions (as well as
other words or expressions referencing future events or
circumstances) are intended to identify forward-looking statements.
Many of these forward-looking statements involve a number of risks
and uncertainties. Among other things, for those statements, the
Company claims the protection of safe harbor for forward-looking
statements contained in the PSLRA. The Company does not undertake
to update any of these forward-looking statements to reflect events
or circumstances that occur after the date hereof.Investor
Contact:
JTC Team, LLCJenene Thomas(833) 475-8247AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024